3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Multiple Myeloma
3
Melanoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Small Cell Lung Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligometastatic Disease
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Dexamethasone
33
Cyclophosphamide
31
fludarabine
19
venetoclax
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
Tretinoin
×
Clear all
NCT02717884
2018-10-18
TRANSATRA
University Hospital Freiburg
Phase 1/2
Unknown
60 enrolled